A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides
Open Access
- 12 September 2006
- journal article
- research article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 55 (5) , 807-813
- https://doi.org/10.1016/j.jaad.2006.06.038
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Immunization With Melan-A Peptide-Pulsed Peripheral Blood Mononuclear Cells Plus Recombinant Human Interleukin-12 Induces Clinical Activity and T-Cell Responses in Advanced MelanomaJournal of Clinical Oncology, 2003
- Functional expression of the eotaxin receptor CCR3 in CD30+ cutaneous T-cell lymphomaBlood, 2003
- Thymus and activation-regulated chemokine (TARC/CCL17) in mycosis fungoides: Serum TARC levels reflect the disease activity of mycosis fungoidesJournal of the American Academy of Dermatology, 2003
- Increased CCR4 Expression in Cutaneous T Cell LymphomaJournal of Investigative Dermatology, 2002
- CUTANEOUS T-CELL LYMPHOMA: New ImmunomodulatorsDermatologic Clinics, 2001
- Differentiation of Resting Human Peripheral Blood γδ T Cells toward Th1- or Th2-PhenotypeCellular Immunology, 2001
- Cutaneous T Cell Lymphoma Reactive CD4+ Cytotoxic T Lymphocyte Clones Display a Th1 Cytokine Profile and Use a Fas-Independent Pathway for Specific Tumor Cell LysisJournal of Investigative Dermatology, 2000
- Proinflammatory and Immunoregulatory Functions of Interleukin-12International Reviews of Immunology, 1998
- Progression of Mycosis Fungoides Is Associated with Increasing Cutaneous Expression of Interleukin-10 mRNAJournal of Investigative Dermatology, 1996
- Th2 Cytokine mRNA Expression in Skin in Cutaneous T-Cell LymphomaJournal of Investigative Dermatology, 1994